This Week in NEJM

Premium

In NEJM this week, researchers from the US, Europe, and Canada present findings from a study of exemestane for the prevention of breast cancer in post-menopausal women. In a randomized, placebo-controlled, double-blind trial of 4,560 women with a median age of 62.5 years, 11 invasive breast cancers were detected in the group randomly assigned to take exemestane, compared to 32 cancers detected in the placebo group, at a median follow-up of 35 months.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.